STRUCTURAL AND CHEMICAL BIOLOGY PROGRAM Lorena S. Beese, Ph.D. and Patrick J. Casey, Ph.D., Co-Leaders The goal of the Program in Structural and Chemical Biology is to provide a molecular description and interpretation of biological processes associated with oncogenesis and tumor progression. This program emerged out of a reorganization of the former Program in Cellular and Structural Biology that was prompted by the growth of this broad area of research at Duke and its increasing cancer relevance and impact on other Programs in the Cancer Center. Together, the tools of structural and chemical biology permit investigation of fundamental aspects of cancer biology, design and discovery of therapeutics, and development of novel molecular and cellular technologies. Program members include those with expertise in X-ray crystallography and NMR analyses as well as enzymology, chemical synthesis, and modeling at the molecular level. Program members provide valuable consultation and technology to other Cancer Center investigators who have identified molecules involved in cellular transformation, and this serves to stimulate the exchange of technology and expertise between members of the Program as well as with other members of the Cancer Center. Program members have provided the leadership for a number of initiatives that have markedly enhanced the technological capabilities available to the cancer community at Duke, including the upgrade and expansion of our X-ray crystallography and NMR facility, establishment of a state-of-the-art proteomics facility, and the establishment of core technologies enabling high-throughput screening of small molecule libraries and follow-up chemical synthesis. The 22 members of this Program have produced 595 publications in the past five years, showing significant intra- and inter-programmatic collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-33
Application #
7726605
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-01-01
Budget End
2007-12-31
Support Year
33
Fiscal Year
2007
Total Cost
$25,321
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31
Abdi, Khadar; Kuo, Chay T (2018) Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev 32:740-741
Lu, Min; Sanderson, Sydney M; Zessin, Amelia et al. (2018) Exercise inhibits tumor growth and central carbon metabolism in patient-derived xenograft models of colorectal cancer. Cancer Metab 6:14
Qian, Danwen; Liu, Hongliang; Wang, Xiaomeng et al. (2018) Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer :
Ashcraft, Kathleen A; Choudhury, Kingshuk Roy; Birer, Sam R et al. (2018) Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion. Radiat Res 190:12-21
Ong, Cecilia T; Campbell, Brittany M; Thomas, Samantha M et al. (2018) Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Ann Surg Oncol 25:2249-2260
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408

Showing the most recent 10 out of 513 publications